IMI 28 en es it fr

IMI 28 Brand names, IMI 28 Analogs

IMI 28 Brand Names Mixture

  • No information avaliable

IMI 28 Chemical_Formula


IMI 28 RX_link

IMI 28 fda sheet


IMI 28 msds (material safety sheet)

IMI 28 Synthesis Reference

Smith et al.; J.Org.Chem.; 42;3653,3658(1977)

IMI 28 Molecular Weight

543.519 g/mol

IMI 28 Melting Point


IMI 28 H2O Solubility

0.093 mg/ml

IMI 28 State


IMI 28 LogP


IMI 28 Dosage Forms

Powder for solution; Solution

IMI 28 Indication

For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer

IMI 28 Pharmacology

Epirubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Epirubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

IMI 28 Absorption


IMI 28 side effects and Toxicity

bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding

IMI 28 Patient Information

Patients should be informed of the expected adverse effects of epirubicin, including gastrointestinal symptoms (nausea, vomiting, diarrhea, and stomatitis) and potential neutropenic complications. Patients should consult their physician if vomiting, dehydration, fever, evidence of infection, symptoms of CHF, or injection-site pain occurs following therapy with ELLENCE. Patients should be informed that they will almost certainly develop alopecia. Patients should be advised that their urine may appear red for 1 to 2 days after administration of ELLENCE and that they should not be alarmed. Patients should understand that there is a risk of irreversible myocardial damage associated with treatment with ELLENCE, as well as a risk of treatment-related leukemia. Because epirubicin may induce chromosomal damage in sperm, men undergoing treatment with ELLENCE should use effective contraceptive methods. Women treated with ELLENCE may develop irreversible amenorrhea, or premature menopause.

IMI 28 Organisms Affected

Humans and other mammals